Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Natera’s genomic jargon isn’t easy. Each 10-K details everything from cfDNA assay accuracy to payer reimbursement disputes, while 8-K updates often cover fast-moving clinical-trial milestones. If you’ve ever wondered how to locate test-volume data, or needed Natera insider trading Form 4 transactions before the market reacts, you know the challenge.
Stock Titan solves it. Our AI reads every Natera quarterly earnings report 10-Q filing, highlights revenue per test, and translates accounting footnotes into plain language. Real-time alerts flag Natera Form 4 insider transactions real-time, so you can track executive stock moves the moment they hit EDGAR. Need the full picture? We link each 10-K, 10-Q, 8-K, proxy DEF 14A, and S-8 in one place—Natera SEC filings explained simply. Common questions such as “How do I find the latest Natera proxy statement executive compensation?” or “Where is the Natera 8-K material events explained?” are answered inside every filing card.
Our platform doesn’t stop at document delivery. AI-powered summaries spotlight what matters for a diagnostics company: R&D spend versus cash on hand, progress of the Signatera oncology pipeline, and changes in CMS reimbursement that can swing margins. Use cases include:
- Compare quarter-over-quarter test volumes without sifting through tables
- Monitor Natera executive stock transactions Form 4 for buying or selling trends
- Assess dilution risk by reviewing shelf registrations and ATM offerings
- Download an Natera annual report 10-K simplified PDF automatically annotated by AI
- Receive instant alerts when a new Natera earnings report filing analysis is available
- Get guidance on understanding Natera SEC documents with AI-generated glossaries
Whether you’re a healthcare analyst, portfolio manager, or clinician-investor, Stock Titan turns Natera’s dense disclosures into actionable insight—no genetics PhD required.
Natera, Inc. (NTRA) – Form 4 filing
CFO Michael Burkes Brophy reported a routine set of transactions tied to RSU vesting and a previously adopted Rule 10b5-1 plan.
- RSU conversion: On 22 Jul 2025, 1,250 restricted stock units vested and were converted to common shares (Code M).
- Share sales: The executive sold 2,170 shares across four trades on 22-24 Jul at weighted-average prices of $139.20-$141.28 to cover tax-withholding and liquidity needs.
- Net change: Beneficial ownership fell by 1,250 shares, leaving Brophy with 70,494 common shares (<≈1.8% reduction) and 1,250 unvested RSUs.
- Plan status: All dispositions were executed under a 10b5-1 plan adopted 14 Jun 2024, limiting discretionary timing.
No other corporate events or material financial information are disclosed in this filing.
FAQ
What is the current stock price of Natera (NTRA)?
What is the market cap of Natera (NTRA)?
